Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects
Закрыть
Расширенный поиск
Site Map
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
668 0
SM ISO690:2012
MCCLURE, Matthew W., BERLIBA, Elina, TSERTSVADZE, Tengiz, STREINU-CERCEL, Adrian, VIJGEN, Leen, ASTRUC, Beatrice, PATAT, Alain A., WESTLAND, Christopher E., CHANDA, Sushmita, ZHANG, Qingling, KAKUDA, Thomas, VUONG, Jennifer, KHORLIN, Nick, BEIGELMAN, Leonid N., BLATT, Lawrence Mitchell, FRY, John. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. In: PLoS ONE, 2018, nr. 10(13), p. 0. ISSN 1932-6203. DOI: https://doi.org/10.1371/journal.pone.0204974
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
PLoS ONE
Numărul 10(13) / 2018 / ISSN 1932-6203

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects
DOI:https://doi.org/10.1371/journal.pone.0204974

Pag. 0-0

McClure Matthew W.1, Berliba Elina2, Tsertsvadze Tengiz3, Streinu-Cercel Adrian4, Vijgen Leen5, Astruc Beatrice6, Patat Alain A.6, Westland Christopher E.1, Chanda Sushmita1, Zhang Qingling1, Kakuda Thomas1, Vuong Jennifer1, Khorlin Nick1, Beigelman Leonid N.1, Blatt Lawrence Mitchell1, Fry John1
 
1 Alios BioPharma, Inc.,
2 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
3 AIDS and Clinical Immunology Research Center of Georgia,
4 University of Medicine and Pharmacy “Carol Davilla”, Bucharest,
5 Janssen Research & Development BE, Beerse,
6 Biotrial
 
 
Disponibil în IBN: 5 decembrie 2018
Rezumat

Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. Methods This three-part randomized, double-blind study evaluated the safety and pharmacokinetics of single and multiple ascending oral doses of AL-335. Healthy volunteers (HVs) received single doses of AL-335 (100-1,200 mg) or placebo in a fasted or fed (400 mg) state. Non-cirrhotic subjects (HCV genotype [GT]1-4) and GT1-infected subjects with Child Pugh A cirrhosis received multiple doses of AL-335 (400, 800, 1,200 mg) or placebo once daily (QD) for 7 days. Results Forty-eight HVs and 64 subjects with HCV GT1-4 were randomized and received treatment. AL-335 was well tolerated in HVs and HCV-infected subjects with/without cirrhosis. AL-335 was rapidly absorbed and converted to the metabolites ALS-022399 and ALS-022227. ALS- 022227 exposure increased less than dose-proportionally and was unaffected by food, while AL-335 and ALS-022399 exposure increased with food by 85% and 50%, respectively, in HVs. Rapid and dose-dependent reductions in HCV-RNA were observed in GT1-infected subjects. In non-cirrhotic, GT1-4-infected subjects receiving AL-335 800 mg QD, potent antiviral activity was observed, regardless of genotype (mean maximum reductions in HCVRNA of 4.0-4.8 log10 IU/mL). The same dose in GT1-infected cirrhotic subjects resulted in a 3.5 log10 IU/mL mean maximum reduction in HCV-RNA. Conclusions AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile. The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-68822</cfResPublId>
<cfResPublDate>2018-10-15</cfResPublDate>
<cfVol>13</cfVol>
<cfIssue>10</cfIssue>
<cfISSN>1932-6203</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/68822</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects</cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. Methods This three-part randomized, double-blind study evaluated the safety and pharmacokinetics of single and multiple ascending oral doses of AL-335. Healthy volunteers (HVs) received single doses of AL-335 (100-1,200 mg) or placebo in a fasted or fed (400 mg) state. Non-cirrhotic subjects (HCV genotype [GT]1-4) and GT1-infected subjects with Child Pugh A cirrhosis received multiple doses of AL-335 (400, 800, 1,200 mg) or placebo once daily (QD) for 7 days. Results Forty-eight HVs and 64 subjects with HCV GT1-4 were randomized and received treatment. AL-335 was well tolerated in HVs and HCV-infected subjects with/without cirrhosis. AL-335 was rapidly absorbed and converted to the metabolites ALS-022399 and ALS-022227. ALS- 022227 exposure increased less than dose-proportionally and was unaffected by food, while AL-335 and ALS-022399 exposure increased with food by 85% and 50%, respectively, in HVs. Rapid and dose-dependent reductions in HCV-RNA were observed in GT1-infected subjects. In non-cirrhotic, GT1-4-infected subjects receiving AL-335 800 mg QD, potent antiviral activity was observed, regardless of genotype (mean maximum reductions in HCVRNA of 4.0-4.8 log10 IU/mL). The same dose in GT1-infected cirrhotic subjects resulted in a 3.5 log10 IU/mL mean maximum reduction in HCV-RNA. Conclusions AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile. The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-63280</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10673</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63358</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63359</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63360</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63361</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63362</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63363</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63364</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63365</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63366</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63367</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63368</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63369</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63370</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63371</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-68822</cfFedIdId>
<cfFedId>10.1371/journal.pone.0204974</cfFedId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-63280</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63280-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>McClure</cfFamilyNames>
<cfFirstNames>Matthew W.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10673</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10673-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Berliba</cfFamilyNames>
<cfFirstNames>Elina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63358</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63358-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Tsertsvadze</cfFamilyNames>
<cfFirstNames>Tengiz</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63359</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63359-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Streinu-Cercel</cfFamilyNames>
<cfFirstNames>Adrian</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63360</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63360-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Vijgen</cfFamilyNames>
<cfFirstNames>Leen</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63361</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63361-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Astruc</cfFamilyNames>
<cfFirstNames>Beatrice</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63362</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63362-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Patat</cfFamilyNames>
<cfFirstNames>Alain A.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63363</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63363-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Westland</cfFamilyNames>
<cfFirstNames>Christopher E.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63364</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63364-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Chanda</cfFamilyNames>
<cfFirstNames>Sushmita</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63365</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63365-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Zhang</cfFamilyNames>
<cfFirstNames>Qingling</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63366</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63366-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Kakuda</cfFamilyNames>
<cfFirstNames>Thomas</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63367</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63367-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Vuong</cfFamilyNames>
<cfFirstNames>Jennifer</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63368</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63368-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Khorlin</cfFamilyNames>
<cfFirstNames>Nick</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63369</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63369-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Beigelman</cfFamilyNames>
<cfFirstNames>Leonid N.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63370</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63370-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Blatt</cfFamilyNames>
<cfFirstNames>Lawrence Mitchell</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63371</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63371-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Fry</cfFamilyNames>
<cfFirstNames>John</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>
Share

Institutul de Dezvoltare a Societatii InformationaleEXPERT on-lineInstitutul de Dezvoltare a Societatii InformationaleCN-2022Indicatori CDIASM

CC-BY-NC

Copyright © 2012 - 2024 Instrument Bibliometric National

Institutul de Dezvoltare a Societatii Informationale All Rights Reserved.

IBN v1.5.5

CSS valid!